ArticleThe Lancet regional health. Southeast Asia2026
A decision-support tool for management of advanced epithelial ovarian cancer in a single centre in India (CT PAUSE Nomogram): a prospective Study (2022-2024).
Article in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate preoperative imaging is essential in advanced epithelial ovarian cancer, where complete cytoreduction remains the strongest prognostic factor. This study evaluates the CT PAUSE score-a structured, domain-based reporting tool-for its utility in surgical planning and multi-disciplinary team (MDT) decision-making. Methods: In this prospective cross-sectional study between September 2022 to February 2024, 124 patients with FIGO stage III/IV ovarian cancer underwent 175 contrast-enhanced CT scans. PAUSE components-Peritoneal Cancer Index (PCI), Ascites/abdominal wall disease, Unfavourable sites, Small bowel/mesenteric disease, and Extra-peritoneal metastases-were prospectively scored during evaluation. Interobserver agreement was assessed in a subset of 30 cases. Findings: MDT triage using PAUSE resulted in a complete cytoreduction rate of 89.3%. A simplified nomogram based on upper abdominal disease volume showed discriminatory ability (area under the curve (AUC) [95% CI] = 0.820 [0.740-0.880]) and could be an alternative to the full radiological PCI-based nomogram (AUC) [95% CI] = 0.763 [0.677-0.835]), in busy clinical settings. Interobserver agreement was substantial for both nomogram scores, with higher reliability observed for the score derived from the upper abdominal disease-based nomogram (intraclass correlation coefficient (ICC) [95% CI] = 0.710 [0.582-0.825] versus 0.627 [0.460-0.778]; p < 0.001). Interpretation: CT PAUSE provides a structured approach to radiological reporting and may support more consistent MDT discussions and surgical triage in advanced ovarian cancer. Its performance in this cohort might suggest potential for integration into clinical workflows, pending further validation. Funding: There was no funding source for this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.